Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Priced IPO
Solaredge Technologies, Inc. (SEDG)
The Marygold Companies (MGLD)
Blue Water Vaccines (BWV)
Meihua International Medical Technologies (MHUA)
Smart for Life (SMFL)
Vivakor (VIVK)
TC BioPharm Holdings (TCBP)
Direct Digital Holdings, Llc (DRCT)
Modiv (MDV)
Sky Technologies (SKYX)
Modular Medical (MODD)
HeartCore Enterprises (HTCR)
Arcellx, Inc. (ACLX)
Silver Spike Investment Corp. (SSIC)
Maris-Tech Ltd. (MTEK)
Yoshitsu Co., Ltd. (TKLF)
Tpg Inc. (TPG)
Hillstream BioPharma (HILS)
Hour Loop (HOUR)
Vigil Neuroscience, Inc. (VIGL)
More companies

Alzamend Neuro (ALZN)

Sector - Healthcare

Price chart

N/A
Return from IPO

Company News

IPO Profile

About company

Company Logo
They were formed to acquire and commercialize patented intellectual property and know-how to prevent, treat and cure the crippling and deadly Alzheimer's disease. Existing Alzheimer's treatments only temporarily relieve symptoms but do not slow or halt the underlying worsening of the disease. They have developed a novel approach in an attempt to combat Alzheimer's through immunotherapy. They are a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. With their two current and future product candidates, they aim to bring treatments or cures to market at a reasonable cost as quickly as possible. Their current pipeline consists of two novel therapeutic drug candidates. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001 or LiProSal, through two royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, as licensor, and AL002 a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as AL002 or CA022W, through a royalty-bearing exclusive worldwide license from the same licensor.
Industry
Pharmaceutical Preparations
CEO CFO
Stephan Jackman Kenneth S. Cragun
Employees Founded
4 2016

Contacts

Address: 3802 Spectrum Boulevard, Suite 112c Tampa, Florida 33612, Us

Telephone: (844) 722-6333

Web page: http://alzamend.com

IPO information

First Trade Date 6/15/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 2.5
Shares Revised (MM) 2.5
Expected offer amount (MM) $12
Realized offer amount(MM) $12.5

Financial Data (last reporting year)

Market Cap (MM) $424.6
Revenues (MM) $0
Net Income (Loss) (MM) $-3.8

Voting

What do you think will happen with the ALZN share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Spartan Securities

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Spartan Securities
CO-Managers

Sector: Healthcare

Tweets about $ALZN

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats